NEW YORK (GenomeWeb) – NanoString said today that it has signed a translational research agreement with MacroGenics to identify and develop biomarkers for MacroGenics' MGD013 program.
As part of the agreement, the two firms will conduct joint research using NanoString's PanCancer IO 360 panel to explore potential signatures for MGD013 clinical applications. NanoString will develop and evaluate the tumor inflammation signature and novel predictive gene expression signature for MGD013.
MGD013 is an IgG4K bispecific DART molecule designed to block PD-1 and LAG-3 pathways, providing improved T-cell activation compared to single or combination monoclonal antibody blockade. The molecule is currently in the dose escalation portion of a Phase 1/2 study, where researchers are evaluating its tolerability and initial safety in advanced solid tumors and hematologic malignancies.
If the collaborators identify a predictive biomarker, they may develop a companion diagnostic for specific clinical applications of MGD013.
"This collaboration presents a unique opportunity to accelerate our MGD013 clinical development by applying NanoString's translational research tools," MacroGenics CEO and President Scott Koenig said in a statement.
Earlier this month, NanoString said it has entered a $100 million term loan facility with the CR Group, a healthcare-focused investment firm.